TW516958B - Water-soluble fullerenol pharmaceutical composition - Google Patents

Water-soluble fullerenol pharmaceutical composition Download PDF

Info

Publication number
TW516958B
TW516958B TW86116108A TW86116108A TW516958B TW 516958 B TW516958 B TW 516958B TW 86116108 A TW86116108 A TW 86116108A TW 86116108 A TW86116108 A TW 86116108A TW 516958 B TW516958 B TW 516958B
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
scope
patent application
item
integer
Prior art date
Application number
TW86116108A
Other languages
Chinese (zh)
Inventor
Lung-Yung Jiang
Feng-Jou Liu
Yuan-De Li
Yi-Lung Lai
Ming-Jeng Tsai
Original Assignee
Nat Science Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Science Council filed Critical Nat Science Council
Priority to TW86116108A priority Critical patent/TW516958B/en
Application granted granted Critical
Publication of TW516958B publication Critical patent/TW516958B/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical composition for treating free radical-induced diseases or syndromes, comprising: an effective amount of compound: F(-X)m wherein, F is a fullerene nucleus; each X is independently -OH, -(CH2)n-SO3H, or the metal salt of -(CH2)n-SO3<SP>-</SP>, wherein, each n is independently an integer of from 2 to 50; and m is an integer of from 2 to 40; and a pharmaceutically acceptable vehicle.

Description

A7A7

516958 五、發明說明(/ ) 共軛籠式烯烴(conjugated caged olefins ),例如碳60 (Cm )或是其類似物,對許多的化學試劑都特別地敏感 性,特別是它們對有機自由基的多重加成反應都展現了高 度的反應性,據推測,此種反應性是與這類分子本身強大 的陰電性有關。 目前已有數種官能基化的芙類衍生物乂 fullerene derivatives)在生化或醫學的相關研究中被提出,例如: 雙(丁二酸-苯乙胺酯)Cm可以抑制HIV-1(後天免疫缺乏病 毒)的蛋白質酵素(見 Friedman,et al·,J. Am. Chem. Soc. 1993, 1 15, 6506),另一個例子為:光活化後的水溶性單官 能基Cm具有分裂DNA的活性,以及對HeLa S3細胞系具 有體外的(in vitro)細胞毒性;但此二種活性都是在光源 的存在下才會產生。 本發明的目的就是提供一種醫藥組成物,以治療自由 基所引起的相關症狀。此種醫藥組成物包括一有效量的聚 羥基化芙類化合物、聚(磺醯基烷基化)芙類化合物或其金屬 鹽、或疋含混合官能基的芙類化合物(亦即同時含有經基 與磺醯基烷基)或是其金屬鹽;以及一藥學上可接受之載 劑0 上述之芙類化合物具有下列通式: F(-X)m 中F為一夫核(亦即c6〇芙核;fuiierene core); 每個X各自獨立地為〇H、(CH2)n_s〇3H、或是(CH2)n S〇f 的金餍鹽,其中每個n各自獨立地為^別:以及⑺為孓 (請先閱讀背面之注意事項再填寫本頁) _ i線· 經濟部智慧財產局員工消費合作社印製 3 經濟部中央標準局員工消費合作社印製 516958 A7 R7 _________________ °7 五、發明测(2 ) ~ &quot;&quot;—---- 40 〇 當X為OH時,m以4-30較佳,最佳為1〇 2〇。另 外當X為(CH2)n-S〇3H、或(CH2)n_s〇3•的金屬鹽時,爪以 2-10較佳,而η以2-10較佳。 當X為(CH2)n-S〇3·的金屬鹽時,此金屬可以是一價 的金屬(如鈉或鉀)或二價的金屬(如鈣或鎂)。 、 所謂的“芙核”為一籠形分子,主要以碳原子為組成 物質例如:c6。,c6〇Hx,c61,c62,QQ,^Νχ, C610x ’ c62ox,c70ox,c710x,C72〇x,C70NX,c76,c76ox, c78 ’ c780x ’ c82 ’ C82Ox ’ c84 ’ C84〇x,c92,c92ox,或 其它相似的分子,其中X的範圍為l_2〇(例如i_8)。 C6〇〇x(〇H)Y就是以C6〇Ox做為芙核而以羥基連結而成英 類衍生物的一個例子。QHJNRR%就是以c6()Hx為芙 核的另一個例子。另外“c6()芙核,,特別是指C6。,c6Qhx, C61 ’ C62 ’ C60Ox,C60Nx,C6i〇x,或 c62ox。 本發明的另一個目的是提供一種治療自由基所引起 之相關症狀的方法,此方法包括:對有此需要的對象供 給有效量的一個或一個以上的上述化合物。 其中F為一芙核;每個X各自獨立地為OH、(CH2)n-S03H、或(CH2)n-S03·的金屬鹽,其中每個η各自獨立地 為2_50 ;以及m為2-40。 本發明的範圍除了以上述之醫藥組成物為自由基去 除劑之外,更包括將此組成物製成藥物,以治療自由基 所引起的相關症狀。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁}516958 V. Description of the invention (/) Conjugated caged olefins, such as carbon 60 (Cm) or the like, are particularly sensitive to many chemical reagents, especially their effect on organic free radicals The multiple addition reactions all exhibit a high degree of reactivity, and it is speculated that this reactivity is related to the strong anions of the molecules themselves. At present, several functionalized hydrazone derivatives (fullerene derivatives) have been proposed in related biochemical or medical research, such as: bis (succinic acid-phenylethylamine) Cm can inhibit HIV-1 (acquired immune deficiency Virus) protein enzymes (see Friedman, et al., J. Am. Chem. Soc. 1993, 1 15, 6506), another example is: water-soluble monofunctional Cm after photoactivation has the activity to split DNA, And in vitro cytotoxicity to the HeLa S3 cell line; however, both of these activities occur in the presence of a light source. The object of the present invention is to provide a medicinal composition to treat the related symptoms caused by free radicals. Such a medicinal composition includes an effective amount of a polyhydroxylated candela compound, a poly (sulfoalkylated) candela compound or a metal salt thereof, or a candela compound containing a mixed functional group (that is, it also contains And sulfofluorenylalkyl) or metal salts thereof; and a pharmaceutically acceptable carrier 0 The above-mentioned fumarium compounds have the following general formula: F (-X) m where F is a monogamous nucleus (ie c6〇 Fu core; fuiierene core); each X is independently a gold salt of 0H, (CH2) n_s〇3H, or (CH2) n S0f, wherein each n is independently ^ different: and ⑺ 为 孓 (Please read the notes on the back before filling out this page) _ i-line · Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs 3 Printed by the Employee Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 516958 A7 R7 _________________ ° 7 V. Invention Measure (2) ~ &quot; &quot; ------ 40 〇 When X is OH, m is preferably 4-30, and most preferably 1020. In addition, when X is a metal salt of (CH2) n-S03H or (CH2) n_s03, a claw is preferably 2-10, and η is preferably 2-10. When X is a metal salt of (CH2) n-S03, the metal may be a monovalent metal (such as sodium or potassium) or a divalent metal (such as calcium or magnesium). The so-called "fu core" is a cage-shaped molecule, mainly composed of carbon atoms. For example: c6. , C6〇Hx, c61, c62, QQ, ^ Nχ, C610x 'c62ox, c70ox, c710x, C72〇x, C70NX, c76, c76ox, c78' c780x 'c82' C82Ox 'c84' C84ox, c92, c92ox, Or other similar molecules, where X ranges from 1 to 20 (eg, i_8). C600x (〇H) Y is an example of an English derivative in which C600Ox is used as a nucleus and linked with a hydroxyl group. QHJNRR% is another example of c6 () Hx as the core. In addition, "c6 (), especially C6., C6Qhx, C61 ', C62', C60Ox, C60Nx, C6iox, or c62ox. Another object of the present invention is to provide a method for treating the symptoms caused by free radicals. A method comprising: supplying an effective amount of one or more of the above compounds to a subject in need thereof, wherein F is a nucleus; each X is independently OH, (CH2) n-S03H, or (CH2 ) a metal salt of n-S03 ·, in which each η is independently 2-50; and m is 2-40. The scope of the present invention includes the above-mentioned pharmaceutical composition as a radical scavenger, and also includes this composition It is made into medicine to treat the related symptoms caused by free radicals. This paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm) (Please read the precautions on the back before filling this page}

516958 五、發明説明( 為讓本發明之上述和其他目的 明顯易懂,下文特兴妒杜# 特徵、和優點能更 文特舉較佳實施例,作詳細說明如下·· 本發明之醫藥組成物可 起的相關症狀,例如可以用編:為/σ療自由基所弓I 、古j τ以用來抑制呼吸道自由基引起伊 '縮、抑制過氧化物引起的腦細胞氧化破壞、抑制自 土引起血蛋白的氧化、抑制血癌細胞與平滑肌細胞的 t生、抑制胃移植引起自由基產生導致的細胞破壞、或 是清除癌症病人血液中的過量自由基。易言之,自由基 引發的相關症狀包括例如··局部缺血導致的支氣管縮 小、再灌流手術中引起的細胞破壞、癌症、動脈硬化、 以及神經上的疾病,例如癲癇症及帕金森症,因此上述 的水溶性芙類化合物也可以用來治療這些症狀。 水溶性的聚羥基化芙類衍生物,例如c6G(〇H)x或 C6〇Ox(〇H)y,其製備方法在此之前已廣為人知。 例如芙醇-1可經由純的Qg或(^(84%)與C7G(i6%) 組成的混合物在室溫下與碗基四氣硼酸在有機竣酸 (RC02H)中反應而得的芙類產物水解而成。(chiang,et al., U.S. Patent 5,177,248; Chiang,et al. U.S· Patent 5,294,732; 經濟部中央標準局員工消費合作社印製 and Chiang, et al.5 J. Am. Chem. Soc. 1992, 114, 10154; Chiang,et al·,J. Am. Chem. Soc. 1993, 115, 5453·)。芙醇 -1的結構為C60Ox(OH)y,其中平均x小於5,y等於18。 另一個例子為芙醇-2可經由純的C6G或C6G(84%)與 C70( 16%)組成的混合物在含三氧化硫(30%)的硫酸溶液中 反應而得的芙產物水解而成。(Chiang,et al·,J· Org Chem· 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 516958 A7 五、發明說明(4 ) 經濟部智慧財產局員工消費合作社印製 1994,59,3960·)。芙醇-2 結構為 C6〇(〇H)y,其中 y 平 均等於12。 聚(續醯基烧基化)芙類化合物或其金屬鹽可經由實 施例1或是其類似的方法合成,若是有需要,可接著進 行羥基化反應。例如底下的實施例i,製備出聚(丁基磺 醯鈉)芙類之後,C60(CH2CH2CH2CH2SO3Na)x,其中x的 大小會隨反應的條件而改變,範圍從2_2〇(平均為4_6 ), 可再利用下面兩段所敘述的方法予以羥基化而得一混合 B 月匕基芙類 C60(CH2CH2CH2CH2SO3Na)x(OH)y,其中 y 的大小會隨反應的條件而改變,範圍從1_2〇 (大部份為 1-10) 〇 目前有許多種分析方法,如以下的實施例2-8,可以 用來筛選出對自由基之相關症狀有療效的水溶性芙類化 合物。 這裡所說的有效量是指:對病人施予這樣的劑量 後’可以使自由基的數量明顯的降低,並且緩和病人因 為過量的自由基所引起的症狀。給予病人的有效量會隨 著病人的年齡、體重、欲治療的疾病、以及病症的程度 而有所不同,最後再由主治醫師作最後的決定。此有效 里通常是根據病患體表面積,病患的重量以及病患情況 的不同來供應給病患。Freireich,E.J·等人在Cancer Chemother· Rep·,50(4):219,1966·中描述 了動物與人體 劑量之相對關係(以mg/m2之體表面積為單位)。體表 面積可以由病患的身高及體重來粗略的估計,例如參考 (請先閱讀背面之注意事項再填寫本頁)516958 V. Description of the invention (In order to make the above and other objects of the present invention obvious and easy to understand, the following features and advantages can be further exemplified by the preferred embodiments, which are described in detail below. The pharmaceutical composition of the present invention Relevant symptoms that can be caused by substances, for example, can be used to edit: I / σ treatment of free radicals, bow I, ancient j τ to inhibit airway free radicals caused by contraction, inhibit peroxide-induced brain cell oxidative damage, inhibit self The soil causes the oxidation of blood proteins, inhibits the growth of blood cancer cells and smooth muscle cells, inhibits cell damage caused by free radicals caused by gastric transplantation, or clears excess free radicals in the blood of cancer patients. In other words, the free radical-induced correlation Symptoms include, for example, bronchoconstriction due to ischemia, cell destruction during reperfusion surgery, cancer, arteriosclerosis, and neurological diseases such as epilepsy and Parkinson's disease. It can be used to treat these symptoms. Water-soluble polyhydroxylated puff derivatives, such as c6G (〇H) x or C60Ox (〇H) y, the preparation method is here For example, phoritol-1 can be reacted with pure base of Qg or (^ (84%) and C7G (i6%) at room temperature with bowl-based tetrakis boric acid in organic acid (RC02H). The obtained saccharin products are hydrolyzed. (Chiang, et al., US Patent 5,177,248; Chiang, et al. US · Patent 5,294,732; printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs and Chiang, et al. 5 J Am. Chem. Soc. 1992, 114, 10154; Chiang, et al ·, J. Am. Chem. Soc. 1993, 115, 5453 ·). The structure of pentanol-1 is C60Ox (OH) y, where the average x is less than 5, and y is equal to 18. Another example is that pentanol-2 can be reacted in a sulfuric acid solution containing sulfur trioxide (30%) via a mixture of pure C6G or C6G (84%) and C70 (16%). The obtained fufu product is hydrolyzed. (Chiang, et al ·, J · Org Chem · This paper size is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) 516958 A7 V. Description of the invention (4) Ministry of Economic Affairs wisdom Printed by the Consumer Cooperatives of the Property Bureau 1994, 59, 3960 ·). The structure of pentanol-2 is C6〇 (〇H) y, where y is equal to 12. On average (continued on the basis of fluorination) Compounds or metal salts thereof can be synthesized by Example 1 or a similar method, and if necessary, can be followed by a hydroxylation reaction. For example, the following Example i, after the poly (butylsulfonium sodium) fu , C60 (CH2CH2CH2CH2SO3Na) x, where the size of x will change with the reaction conditions, ranging from 2_20 (average 4_6), can be hydroxylated using the methods described in the following two paragraphs to obtain a mixed B moonyl Husband C60 (CH2CH2CH2CH2SO3Na) x (OH) y, where the size of y will change with the reaction conditions, ranging from 1_2〇 (mostly 1-10). There are currently many analytical methods, such as the following examples 2-8, can be used to screen out water-soluble fusiform compounds that have curative effects on free radical-related symptoms. The effective amount herein means that after administration of such a dose to a patient ', the amount of free radicals can be significantly reduced, and the symptoms of the patient due to excessive free radicals can be alleviated. The effective amount given to a patient will vary depending on the patient's age, weight, the disease to be treated, and the extent of the condition, and the final decision will be made by the attending physician. This is usually provided to patients based on the patient's body surface area, patient weight, and patient condition. Freireich, E.J., et al., Cancer Chemother. Rep., 50 (4): 219, 1966, described the relative relationship between animal and human doses (in mg / m2 body surface area). The body surface area can be roughly estimated by the patient's height and weight, such as reference (please read the precautions on the back before filling this page)

516958 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(5 ) Scientific Tables, Geigy Pharmaceuticals, Ardley, New York,pages 537-538, 1970。本發明中有效量的化合物, 範圍約從5mg/kg到500mg/kg,較佳約從5mg/kg到 250mg/kg’最好是約從5mg/kg到150mg/kg。如熟悉此 技藝者所知,有效劑量亦會隨著以下條件的不同而變 化,包括:投藥的途徑,賦形劑劑量以及併用其他治療 法的可能性,如其他抗癌劑或放射線療法。 配方可製成較方便的單位劑量形式,並可由任何已 知的葯學技藝來製造。所有的方法都包括了將此活性成 份與具有一種或多種附屬成分的載體結合。通常葯錠或 葯粉配方是將此活性成分與已粉碎完全的固體載體相互 4曰’右要成為葯鍵則再將推合後的產物塑造成一定的 大小和形狀即可。既然此活性的芙類化合物為水溶性, 因此載體就使用水溶性載體即可。 上述之化合物可以經由任何適當的途徑投與給病 人,較佳是經由血液注射的方式,但熟悉此技藝者可知, 所運用的途徑,如靜脈内、皮下、肌肉内、腹膜内、鼻 腔、或口服等等,會隨著欲治療的症狀以及所使用的類 似物活性不同而有所差異。 凡是熟悉此技藝之人士在本發明說明之下應可對本 發明完全的利用。以下實施例僅用以舉例說明本發明而 不限制任何的其他運用。 水溶性聚(丁基績醯鈉)芙類衍生物 “(CHzCHzCE^CH^SC^NaL或聚(丙基續醯鈉)芙類衍生 (請先閲讀背面之注意事項再填寫本頁)516958 A7 B7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (5) Scientific Tables, Geigy Pharmaceuticals, Ardley, New York, pages 537-538, 1970. The effective amount of the compound in the present invention ranges from about 5 mg / kg to 500 mg / kg, preferably from about 5 mg / kg to 250 mg / kg ', and most preferably from about 5 mg / kg to 150 mg / kg. As known to those skilled in the art, the effective dose will also vary depending on the following conditions, including the route of administration, the dose of excipients, and the possibility of combining other treatments, such as other anticancer agents or radiation therapy. The formulation can be made into a convenient unit dosage form and can be made by any known pharmaceutical technique. All methods include combining the active ingredient with a carrier having one or more accessory ingredients. Usually, the formula of medicine tablets or powders is to mix the active ingredient with the solid carrier that has been completely crushed. If you want to become a medicine bond, you can shape the pushed product into a certain size and shape. Since this active almond compound is water-soluble, a water-soluble carrier may be used as the carrier. The above compounds can be administered to patients by any suitable route, preferably by blood injection, but those skilled in the art will know that the route used, such as intravenous, subcutaneous, intramuscular, intraperitoneal, nasal cavity, or Oral and the like will vary depending on the symptoms to be treated and the activity of the analogs used. Those skilled in the art should fully utilize the present invention under the description of the present invention. The following examples are only used to illustrate the present invention and not to limit any other applications. Water-soluble poly (butyl sodium sulfonate) fu derivatives "(CHzCHzCE ^ CH ^ SC ^ NaL or poly (propyl sodium sulfonate) fu derivatives) (Please read the precautions on the back before filling this page)

訂I f 0 I —ϋ - Β 7 明58 A7 五、 經 濟 部 智 慧 財 產 局 員 工 消 費 合 作 社 印 製 發明說明(6)物 C60(CH2CH2CH2SO3Na)x 的合成 將一個裝有磁石攪拌器的100毫升的圓底瓶A利用 一隔膜封裝並通入氮氣,在燒瓶中加入5〇〇毫克的芙類 (此芙類可為純Cm或芙類混合物)、4〇毫升甲苯以及 丁烷磺内酯或丨,3-丙烷磺内酯(i,3_pr〇叩如 sultone;與芙類為5至2〇的當量比)。將混合液以分 子篩(4A )予以乾燥。在另一燒瓶b,中,將奈(與芙類 為5至20的當里比)溶解於毫升經過分子|帛(4人) 乾燥後的二甲氧基乙院(DME )中,並將納(與芙類為 5至20當量比)與之反應,得到一呈綠色溶液的奈基鈉。 奈基鈉溶液經過注射管加入燒瓶A内,在氮氣中再將此 此β物在至溫下稅拌4小時’等反應結束時,加入2毫 升的水將所有的反應性中間物驟冷,再將最後的溶液加 入60毫升的甲醇使棕色固體沈澱,再以離心分離之。 、、二過甲醇沖洗2次後(每次2 0毫升),以4 0 °C真空乾 燥後可獲得水溶性聚(丁基磺醯鈉)芙類衍生物 C6〇(CH2CH2CH2CH2S〇3Na)x或聚(丙基確醯納)芙類衍生 物C60(CH2CH2CH2SO3Na)x的棕色固體,其中X的數值 會隨奈基鈉的使用量而變化。聚(烧化績醯鈉)芙類衍生 物的 IR 數據為:IRVmax (KBr) : 1642,1570,1384,1192,1038 5 797 ? 750 5 603 5 534cm'1 °复芙醇-1 (fullerenoM)的抗氧化效果 在缺氧的情況下,例如出血或驅血導致的局部缺 血’在呼吸道組織產生的氧衍生自由基會隨著失血狀態 的開始而快速地增加(Frank,J. Appl· Physiol·,1982, 53, 本紙張尺度適用中國國家標準(qsjs)A4規格(210 χ 297公釐 (請先閱讀背面之注咅?事項再填寫本頁) 訂· |線_ 經濟部中央標準局員工消費合作社印製 516958 A7 B7 五、發明説明(7 ) &quot; 475; Prasad,et al· Angiology,1988,12,1005)。經由體内 中樞神經系統的新陳代謝,會同時產生過氧化物陰離子 與過氧化氫(Halliwell,J. Neurochem·,1992,59,1609), 而鐵錯合物會與過氧化物陰離子或過氧化氫反應,繼而 形成反應性最強的羥自由基。氧衍生自由基(oxygen_ derived radical),特別是羥自由基,會活化傳入c_纖維 (afferent C-fibers) ’ 繼而釋放出 tachykinins。所釋放的 tachykinins會引起非膽素激導性的呼吸道收縮。除了支 氣管的收縮外,反應性的氧自由基還會導致黏液分泌, 以及造成微血管破裂而形成水腫(Cees,et al. Free Radicals Biol. Med·,1990, 9, 381)。以下所述的分析方法 是用來測試芙醇· 1對失血所引起的呼吸道快速收縮的抑 制效果。 JL醇-1對豬隻肺功能的急性副作用測誠 以芙醇-1來測試是否會導致肺功能的急性副作用。 將⑽隻體重約29〇±18公斤的豬隻(Hartly strain guinea pigs)任意分成六組:靜脈内鹽液·,氣管内鹽液、靜脈内 芙醇-1 (1)、氣管内芙醇-1 (1)、靜脈内芙醇(2)、氣管 内芙醇-1 (2)。每隻動物都以戊巴比妥酸鈉(扣士以㈤ pentobarital; 30-50mg/kg)使其麻痒。靜脈内鹽液這組的 動物是經由靜脈内注射入〇.75ml的食鹽水,而氣管内鹽 液的這組動物則是經由氣管内滴注相同量的食鹽水。在 芙醇-1 (1)的這兩組,是分別經由氣管與靜脈兩種途徑對 每隻動物施予200mg/kg(以0.75ml的溶液)的笑醇_丨。在 (請先閱讀背面之注意事項再填寫本頁)Order I f 0 I —ϋ-Β 7 Ming 58 A7 V. Printed invention description printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs (6) Synthesis of object C60 (CH2CH2CH2SO3Na) x A 100 ml circle equipped with a magnetic stirrer Bottom bottle A is sealed with a septum and filled with nitrogen. Into the flask, 500 mg of saccharum (this saccharum can be pure Cm or saccharin mixture), 40 ml of toluene and butanesultone or 丨, 3-propane sultone (i, 3_pr〇 叩 such as sultone; 5 to 20 equivalent ratio to sulcus). The mixture was dried with a molecular sieve (4A). In another flask b, dissolve Nai (Danli ratio of 5 to 20) with dimethoxyethane (DME) which has been dried by molecular | 帛 (4 persons), and Sodium (5 to 20 equivalents ratio to fumars) reacts with it to give a sodium solution of sodium nyl. The sodium nyl solution was added into flask A through an injection tube, and the β substance was stirred under nitrogen for 4 hours at the temperature. When the reaction was completed, 2 ml of water was added to quench all the reactive intermediates. The final solution was added to 60 ml of methanol to precipitate a brown solid, which was then separated by centrifugation. After rinsing twice with methanol (20 ml each time) and vacuum drying at 40 ° C, water-soluble poly (butylsulfosulfonyl) furan derivative C6〇 (CH2CH2CH2CH2S〇3Na) x or The brown solid of poly (propyl cerana) fu derivatives C60 (CH2CH2CH2SO3Na) x, where the value of X will change with the amount of sodium naphthyl used. The IR data of poly (calcined sodium glutamate) derivatives are: IRVmax (KBr): 1642, 1570, 1384, 1192, 1038 5 797? 750 5 603 5 534cm'1 ° fullerenoM-1 Antioxidant effect In the absence of oxygen, such as ischemia caused by bleeding or exsanguination, the oxygen-derived free radicals generated in the respiratory tissues increase rapidly with the onset of blood loss (Frank, J. Appl · Physiol · , 1982, 53, This paper size is in accordance with Chinese national standard (qsjs) A4 specification (210 x 297 mm (please read the note on the back? Matters before filling out this page) Order · | Line _ Staff Consumption of Central Bureau of Standards, Ministry of Economic Affairs Printed by the cooperative 516958 A7 B7 5. Description of the invention (7) &quot;475; Prasad, et al. Angiology, 1988, 12, 1005). Through the metabolism of the central nervous system in the body, peroxide anions and peroxidation will be produced at the same time Hydrogen (Halliwell, J. Neurochem., 1992, 59, 1609), and iron complexes will react with peroxide anions or hydrogen peroxide to form the most reactive hydroxyl radical. Oxygen derived radical radical), especially Hydroxyl free radicals activate afferent C-fibers' and then release tachykinins. The released tachykinins cause non-cholinergic airway contractions. In addition to bronchoconstriction, reactive oxygen free It also causes mucus secretion and edema due to microvascular rupture (Cees, et al. Free Radicals Biol. Med ·, 1990, 9, 381). The analysis method described below is used to test phoritol · 1 for blood loss Inhibitory effect of rapid contraction of the respiratory tract caused by the acute side effects of JL alcohol-1 on the lung function of pigs The pigs (Hartly strain guinea pigs) were randomly divided into six groups: intravenous saline, intratracheal saline, intravenous salivary -1 (1), tracheal-1 (1), intravenous salivary ( 2) Intratracheal -1 (2). Each animal was itched with sodium pentobarbital (Pentobarital; 30-50mg / kg). Animals in this group were intravenously saline Intravenous injection of 0.75 ml of saline and intratracheal salt In this group of animals, the same amount of saline was instilled through the trachea. In the two groups of pentanol-1 (1), 200 mg / kg (by 0.75ml of solution) laughol. (Please read the notes on the back before filling this page)

9 516958 五 經濟部中央標準局員工消費合作社印製 A7 ______B7 發明説明(8 ) 芙醇-1 (2)的這兩組,是分別經由氣管與靜脈兩種途經對 每隻動物施予2mg/kg(以0.75ml的溶液)的芙醇]。經過 與靜脈内鹽液與氣管内鹽液這兩組的比較,除非是以高 劑量(200 mg/kg)經由氣管内滴灌,否則芙醇]的供給並 沒有引起呼吸功能明顯的異常,這表示此化合物對支氣 管並不會產生副作用。 以上述的方法施予鹽液或芙醇-1經過3 0分鐘後, 進行肺功能的測試。將32隻重約229土5公斤的年輕公 豬平均分成四組:控制組、慢性缺氧組、芙醇-1組、以 及deferoxamine mesylate組。控制組的動物被放置在沒 有次氣壓的開放低壓室,而慢性缺氧組的動物被放置在 380 Torr的封閉低壓室7天。這些動物在一天中只有下 午5點到早上8點暴露在缺氧的條件下(間歇性暴露), 其餘的時間則暴露在室内空氣中。芙醇-1這組的動物, 在開始功能性研究的前兩天,經由腹膜將注射人 10mg/kg/day的芙酵-1,並且在驅血前的30分鐘,經由 靜脈再注射入2mg/kg的芙醇·1。每隻動物都以戊巴比妥 酸鈉(30-50mg/kg)使其麻痒並插入導管。在人工呼吸器 (Harvard Rodent Respirator; Model 680)進行人工換氣的 期間,將每隻豬以仰臥方式置於全身體積變化描記器 中,當氣壓流穿描記器的三層鐵絲網(325-mesh)時,其 流量是以Validyne DP 45的差壓轉換器加以監視。肺活 量的變化則由流量的積分而得。最大呼氣流量(MEFV)的 操作是以Buxco Pulmonary操作系統(sharon,CT)來執 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先聞讀背面之注意事項再填寫本頁)9 516958 A7 printed by the Consumer Cooperatives of the Central Standards Bureau of the Five Ministry of Economic Affairs ______B7 Invention Description (8) The two groups of pentanol-1 (2) are administered to each animal through the trachea and vein by 2mg / kg (In 0.75 ml of solution) phoritol]. After comparison with the two groups of intravenous saline and intratracheal saline, unless the high-dose (200 mg / kg) drip was administered through the trachea, the supply of pentanol] did not cause significant abnormalities in respiratory function, which indicates that This compound has no side effects on the bronchi. After 30 minutes of administering the salt solution or phorbol-1 in the manner described above, a lung function test was performed. Thirty-two young boars weighing approximately 229 to 5 kg were divided into four groups on average: the control group, the chronic hypoxia group, the pentanol-1 group, and the deferoxamine mesylate group. Animals in the control group were placed in an open low-pressure chamber without sub-atmospheric pressure, while animals in the chronic hypoxia group were placed in a closed low-pressure chamber at 380 Torr for 7 days. These animals were exposed to hypoxic conditions (intermittent exposure) from 5 noon to 8 am during the day, and the rest of the day were exposed to indoor air. Animals in the phorbol-1 group were injected with human 10 mg / kg / day fuzyme-1 via the peritoneum two days before the start of the functional study, and 2 mg were reinjected via the vein 30 minutes before the blood drive. / kg of phoritol · 1. Each animal was itchy with sodium pentobarbital (30-50 mg / kg) and inserted into a catheter. During artificial ventilation of a respirator (Harvard Rodent Respirator; Model 680), each pig was placed supine in a whole body volume change angiograph, and when the air pressure flow passed through the three-layer barbed wire (325-mesh) of the logger At that time, the flow is monitored with a differential pressure converter from Validyne DP 45. The change in vital capacity is obtained by integrating the flow. The operation of the maximum expiratory flow (MEFV) is based on the Buxco Pulmonary operating system (sharon, CT). The paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm). (Please read the precautions on the back before filling (This page)

經濟部中央標準局員工消費合作社印製 516958 A7 -------- - B7 五、發明説明(^~)~&quot;&quot; '一—'- 行,將肺吹張至總肺活量(氣道開口氣壓約3〇emH2〇的 肺活量)四次,在第四次吹張達到最大容積時,將吹張用 的螺旋閥關閉,而另一個除脹用的螺旋閥會立刻自動打 開。此除脹閥連接至一個20升的容器,其保持在_ 4〇CmH2〇的次氣壓。在此同時,電腦程式會^容積-時 間圖中挑出ο·ι秒的用力呼氣量(FEV〇 i)。在每次mefv 操作之前與之後,會定出功能性剩餘容量(FRC)。從frc 開f,以標準的0·5%氖氣混合氣體將肺吹張至5〇%肺 活畺,再將平衡後的混合氣體抽回並加以分析。將總容 積減去儀器的閒置空間(dead space)即得到frc值。接 著將動物下腹部的主動脈切斷進行驅血,停止人工換 氣,並在驅血開始後的第5、1〇、15、20、25、30分鐘 進行MEFV的操作。FEV()1值用來作為支氣管收縮的指 標(呼吸道尺寸的改變)。 釋出質P測定芙醇-1對呼吸道快速收縮的抑制效旲 上述的測試完成後,立刻以Saria的方法(Saria,et al Am· Rev· Respir· Dis·,137, 133〇, 1998)從豬隻的肺部萃 取出肺釋出質 P(lung substance P ; —種 tachykinin)。以 Cayman Chemical Co·製造的酵素免疫分析套組(Ann Arbor,MI)測量釋出質P的數量。此分析法的原理是基 於自由的釋出質P追蹤劑(釋出質p連接至乙醯膽素酯酶) 對限量的兔抗血清結合位置的競爭。釋出質P追蹤劑的 濃度保持一定,而自由釋出質P的濃度會隨時間改變。 因此’能與兔抗血清結合的釋出質P追縱劑的數量,恰 11 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)— ~ (請先閲讀背面之注意事項再填寫本頁)Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 516958 A7 ---------B7 V. Description of Invention (^ ~) ~ &quot; &quot; '一 —'- OK, blow the lungs to the total vital capacity ( The airway opening air pressure is about 30emH20, the vital capacity) four times. When the fourth blow reaches the maximum volume, the screw valve for blow is closed, and the other screw valve for debulking is automatically opened immediately. This debulking valve is connected to a 20 liter container, which is maintained at a sub-atmospheric pressure of -40 CmH20. At the same time, the computer program selects a forced expiratory volume (FEV0i) of ο · m seconds in the volume-time diagram. A functional residual capacity (FRC) is determined before and after each mefv operation. From frc to f, blow the lungs to 50% lung activity with a standard 0.5% neon gas mixture, and then draw back the equilibrium gas mixture and analyze it. The total volume is subtracted from the dead space of the instrument to get the frc value. Then, the aorta of the animal's lower abdomen was cut off to drive blood, artificial ventilation was stopped, and MEFV was performed at 5, 10, 15, 20, 25, and 30 minutes after the start of blood drive. The FEV () 1 value is used as an indicator of bronchoconstriction (change in airway size). Released P was used to determine the inhibitory effect of phoritol-1 on rapid contraction of the respiratory tract. Immediately after the above test was completed, the method of Saria (Saria, et al Am Rev. Respir Dis, 137, 133, 1998) was used. The lungs of pigs were extracted with lung substance P (tachykinin). The amount of released P was measured with an enzyme immunoassay kit (Ann Arbor, MI) manufactured by Cayman Chemical Co. The principle of this analysis is based on the competition of a limited amount of rabbit antisera binding sites with a free-release P-tracer (linkage of p-linked to acetylcholinesterase). The concentration of the released P tracer remains constant, while the concentration of the freely released P changes over time. Therefore, the amount of release P chasing agent that can be combined with rabbit antiserum is exactly 11 paper sizes applicable to China National Standard (CNS) A4 specifications (210X297 mm) — ~ (Please read the precautions on the back before filling (This page)

516958 Α7 Β7 五、發明説明(i〇 ) 與凹槽中自由釋出質P的濃度成反比。所形成的兔抗血 清-釋出質P錯合物會黏在先前已附於凹槽上的單株抗 體。先洗去那些沒有黏上的試劑,再加入Ellman’s試劑 (含有乙醯膽素酯酶的酵解物)。此酵化反應的產物具有 明顯的黃色,並在412nm具有強烈的吸收,其吸收度與 樣品中的釋出質P成反比。 以中性胜肽内酵素活性測定芙醇-1對呼吸道快速收縮的 抑制效果 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) 以修正過的Orlowski法,測定氣管的中性胜肽内 酵素活性(Orlowski et al. Biochemistry,20, 4942,1981 and Haxhiu-Poskurica, et al. J. Appl. Physiol. 72,1090, 1992)。將冷凍的氣管融解,切成包含50mM Tris的管子 (pH 7.4)。將所得組織在4°C下以音波震盪30秒,並在 17500克離心15分鐘後,將表層浮物(組織抽出物)取出 加以分析。反應的混合物(250ml)包括50ml的組織抽出 物、1.25mM 的 glutaryl_alanine-alanine_phenylalanine_4-methoxy-2-naphthylamine酵化物、10mg的白胺酸胺基月太 酶(leucine aminopeptidase)、以及 50mM Tris 緩衝液(pH 7.4)。將樣品在37°C下培養1小時後,以2% Brij 35的 石榴石GBC(0.0025%的溶液2ml)將產物染色,得到波長 530nm的吸收峰。2-萘胺的釋出量以消失係數加以計算, 且每項實驗都以兩組進行。將每個抽出物的50ml可分 量,在室溫下以 8xl(T7M phosphoramidon 的 50mM Tris 緩衝液(pH 7.4)作15分鐘的前培養。將酵化物、白胺酸 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 經濟部中央標準局員工消費合作社印製 516958 A7 B7 五、發明説明μ ) ~ &quot;~~~ 胺基肽酶、以及室溫培養下的混合物加入此溶液中。氣 管的蛋白質濃度是以牛血清蛋白為基準來加以決定。具 有phosphoramidon抑制性的中性胜肽内酵素活性是以: 每毫克蛋白質在每小時釋放的2-萘胺的數量(nmole)來表 示。 堂祕例3 :芙醇-1對過氧化氫引起的腦細胞氧化破壞的 抑制效果 將10(M 40g的Wistar雄鼠用乙醚麻醉後將頭斬斷, 並迅速將海馬(hippocampi)取出置於冰束的氧化(95% 〇2 與5% COD人工腦脊液,其包含下列成分(mM) : Naci 124、KC1 4·0、ΚΗ2Ρ04 1.0、MgCl2.6H20 1·0、CaCl2 2·5、516958 Α7 Β7 5. Description of the invention (i0) is inversely proportional to the concentration of freely released substance P in the groove. The resulting rabbit anti-serum clear-released P complex will stick to the individual antibodies previously attached to the grooves. Wash off the unattached reagents before adding Ellman ’s reagent (an enzyme containing acetylcholinesterase). The product of this fermentation reaction has a distinct yellow color and strong absorption at 412 nm, and its absorption is inversely proportional to the released substance P in the sample. The inhibitory effect of pentanol-1 on rapid airway contraction was measured by the activity of a neutral peptide enzyme. Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs (please read the precautions on the back before filling this page). Neutrapeptide endoenzyme activity was measured in the trachea (Orlowski et al. Biochemistry, 20, 4942, 1981 and Haxhiu-Poskurica, et al. J. Appl. Physiol. 72, 1090, 1992). The frozen trachea was thawed and cut into tubes containing 50 mM Tris (pH 7.4). The obtained tissue was sonicated at 4 ° C for 30 seconds, and centrifuged at 17,500 g for 15 minutes, and then the surface float (tissue extract) was taken out for analysis. The reaction mixture (250 ml) includes 50 ml of tissue extract, 1.25 mM glutaryl_alanine-alanine_phenylalanine_4-methoxy-2-naphthylamine enzyme, 10 mg of leucine aminopeptidase, and 50 mM Tris buffer (pH 7.4). After the sample was incubated at 37 ° C for 1 hour, the product was stained with 2% Brij 35 garnet GBC (0.0025% solution 2ml) to obtain an absorption peak at a wavelength of 530 nm. The amount of 2-naphthylamine released was calculated using the disappearance coefficient, and each experiment was performed in two groups. A 50ml portion of each extract was pre-cultured at room temperature for 15 minutes with 8xl (T7M phosphoramidon's 50mM Tris buffer (pH 7.4)). The enzyme and leucine were applied to Chinese paper standards ( CNS) A4 (210 × 297 mm) Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 516958 A7 B7 V. Description of the invention μ) ~ &quot; ~~~ Amino peptidase and the mixture at room temperature are added to this solution . The protein concentration in the trachea was determined based on bovine serum protein. The activity of a neutral peptide with phosphoramidon inhibitory activity is expressed as: the amount of 2-naphthylamine (nmole) released per milligram of protein per hour. Mystery Example 3: Inhibitory Effect of Alcohol-1 on Oxidative Damage to Brain Cells Induced by Hydrogen Peroxide 10 (M 40g Wistar male rats were anesthetized with ether, their heads were cut off, and hippocampi was quickly removed and placed in Oxidation of ice bundles (95% 〇2 and 5% COD artificial cerebrospinal fluid, which contains the following components (mM): Naci 124, KC1 4.0 ·, κ 2P04 1.0, MgCl2.6H20 1 · 0, CaCl2 2 · 5,

NaHC03 26、以及葡萄糖ΐ〇·〇。以Sorval組織切具從海 馬顳中隔的中間區域(以垂直於此結構長軸的方向)切下 厚約400mm的切片,然後將其置於33-35°C的記錄室。 將環繞著記錄室的水浴通以95% 02與5% C02的混合氣 體’使流體的高度維持在切片上表面的上方,並將灌流 的速率維持在6.0ml/min。這些切片在使用之前先培養1 小時。 海馬切片的刺激與記錄是以二極式的刺激電極來進 行’其包括直徑300mm,用鐵氟龍絕緣的不鏽鋼線,以 及銀-氣化銀線。在顯微鏡的輔助下將刺激電極放置在放 射層,以作Schaffer側神經束到CA1錐狀細胞的順向刺 激。刺激的條件是用0.1 ms的5-15V矩形脈波,低頻刺 激是採用0·2Ηζ的頻率,細胞外記錄電極以CA1的頂層 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁)NaHC03 26, and glucose OO. A Sorval tissue cutter was used to cut a section about 400 mm thick from the middle area of the hippocampal temporal septum (in a direction perpendicular to the long axis of the structure), and then placed it in a recording room at 33-35 ° C. The water bath surrounding the recording chamber was mixed with 95% 02 and 5% C02 gas mixture 'to maintain the height of the fluid above the upper surface of the section, and the perfusion rate was maintained at 6.0 ml / min. These sections were incubated for 1 hour before use. Stimulation and recording of hippocampal slices were performed using a two-pole stimulation electrode, which included a 300 mm diameter stainless steel wire insulated with Teflon, and a silver-gasified silver wire. With the help of a microscope, the stimulating electrode was placed on the radiation layer for forward stimulation of Schaffer's side nerve bundles to CA1 cone cells. The stimulation conditions were a rectangular pulse of 5-15V at 0.1 ms, and a low-frequency stimulation at a frequency of 0 · 2Ηζ. The extracellular recording electrode was at the top layer of CA1. The paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm). (Please read the notes on the back before filling this page)

516958 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(12 ) 來記錄艇體的反應。尖峰群(population spikes)的振幅為 刺激強度的函數,因此增加刺激強度也會提高尖峰群的 振幅。在實驗中是使用能達到最大振幅二分之一的刺激 強度’並在整個過程中保持同樣的刺激強度。在一對刺 激脈波中’是以50ms的時間作為間隔。第二尖峰群與 第一尖峰群振幅的百分比差即當作此對脈波的促進值。 作為接义個切片並開始記錄的標準為:最大的刺激可 引起至少5mV振幅的單一尖峰群。將刺激電壓加以調 整,以達到約3_5mV之基準線尖峰群的二分之一最大振 幅。 CA1尖峰群的振幅記錄為3 9±〇2mv(n=13),此振 幅在培養進行200分鐘以後仍然維持著同樣的等級。CA1 尖峰群的振幅會隨著過氧化氫的濃度影響而降低,當過 氧化氲的/辰度超過0 006%時,會使尖峰群的振幅降低。 當過氧化氫的供給經過10分鐘以後(〇 〇〇4%、〇 〇〇6%、 0.008/〇、及〇·〇2〇/。),CA1弓|起的尖峰群的振幅會分別下 降至前藥控制級數的 98·0±1β0%(η=3)、32 3±4·9%(η=8)、 15·2±2.8%(η=3)、以及 8·2±2·9%(η=3)。 偵測不出芙醇-l(l〇〇mM)本身對海馬切片有任何的 副作用,在供給經過5分鐘,10分鐘,15分鐘後,所顯 示的CA1尖峰群的振幅分別為1〇3.5土〇.5%(『5), 1〇5.5±〇.5%㈣),應.5±1.5%(n=3)。過氧化氫的供給經 過10分鐘後(〇._%),尖峰群的振幅會隨著時間急速衰 退到32.3±4·9%(η=8)。而在另一個供給芙醇_1(1〇〇福 (請先閲讀背面之注意事項再填寫本頁)516958 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs A7 B7 V. Description of Invention (12) to record the response of the hull. The amplitude of population spikes is a function of the intensity of the stimulus, so increasing the intensity of the stimulus will also increase the amplitude of the spikes. In the experiment, the stimulus intensity which can reach one-half of the maximum amplitude was used and the same stimulus intensity was maintained throughout the process. In a pair of stimulating pulses, the time interval is 50 ms. The percentage difference between the amplitude of the second spike group and the first spike group is taken as the promotion value of the pulse wave. The criterion for taking a slice and starting recording is: the largest stimulus can cause a single spike group with an amplitude of at least 5mV. Adjust the stimulus voltage to achieve a maximum amplitude of one-half of the baseline spike group of about 3_5mV. The amplitude of the CA1 spike group was recorded as 39 ± 0 2 mv (n = 13), and this amplitude was maintained at the same level after 200 minutes of culture. The amplitude of the CA1 spike group will decrease with the influence of the concentration of hydrogen peroxide. When the ratio of thorium peroxide / Chen exceeds 0 006%, the amplitude of the spike group will decrease. After the supply of hydrogen peroxide has passed for 10 minutes (004%, 0.006%, 0.008 / 〇, and 0.002 /.), The amplitude of the peak group of the CA1 bow will decrease to The prodrug control level is 98 · 0 ± 1β0% (η = 3), 32 3 ± 4 · 9% (η = 8), 15 · 2 ± 2.8% (η = 3), and 8 · 2 ± 2 · 9% (η = 3). No side effects of furfurol-l (100 mM) on hippocampal slices were detected. After 5 minutes, 10 minutes, and 15 minutes of feeding, the amplitude of the CA1 spike group displayed was 103.5 soil. 0.5% ("5", 105.5 ± 0.5%), should be .5 ± 1.5% (n = 3). After the supply of hydrogen peroxide has passed for 10 minutes (0 ._%), the amplitude of the peak group rapidly decays with time to 32.3 ± 4.9% (η = 8). And in another supply phoritol_1 (1〇〇 福 (please read the precautions on the back before filling this page)

14 經濟部中央標準局員工消費合作社印製 516958 A7 '&quot;~· ----*------Β7 五、發明説明(13 ) — ' 的實驗中’其尖峰群的振幅為前藥控制振幅級數之 ι〇3.ο±〇·5 %(η=5)。加入過氧化氫經@⑺分鐘後,振幅 下降到74.6±5.5%㈣)。以過氧化氫取代芙醇」介質溶 液進行相同的實驗’過氧化氫—樣會對神經反應產生類 似的抑制行為。 复魅L1·芙醇-1對異丙笨化過氧化氫引起的腦細胞氧 化破壞的抑制效果 以類似實施例3的實驗步驟進行本實施例。海馬切 片的CA1尖峰群隨著異丙苯化過氧化氫(cumene hydroperoxide)的濃度影響而降低其振幅。加入〇.5mM 與LOmM的異丙苯化過氧化氫經過15分鐘後,CA1尖 峰群的振幅分別下降至控制振幅級數的7〇·5±2·4%(η=3) 及34·5±5·4%(η=5)。若是這些海馬切片在加入異丙苯化 過氧化氫之前先以芙醇-1培養5分鐘,尖峰群振幅為前 藥控制振幅級數之1〇2.8±1·9%(η=4)。加入入異丙苯化過 氧化氫經過15分鐘後,振幅下降至75·6±31%(η=4),強 度大約是沒有加芙醇-1的2.11倍。 复施例5 ·芙醇―1對再灌流手術所引起細胞破壞的防制 效果 藉由進行狗的自動移植手術來評估芙醇_ 1對再灌流 手術中自由基掃除效果。將雜種狗(每組n=8_ i 0)麻醉後, 從腹膜中線切開以進行兩側的腎切除手術。切下的腎臟 經過一段時間的失血後,浸在4°C的灌流液。經過24小 時的低溫儲藏後,再植入同一隻狗的皮下子宮頸凹陷。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁)14 Printed by the Employees 'Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 516958 A7' &quot; ~ * ---- * ------ B7 V. Description of the invention (13) — 'In the experiment', the amplitude of its peak group is the former The drug control amplitude series was ι03.ο ± 0.5% (η = 5). After adding hydrogen peroxide for @ ⑺ minutes, the amplitude dropped to 74.6 ± 5.5% ㈣). The same experiment was performed with "hydrogen peroxide instead of pentanol" medium solution-hydrogen peroxide-which would have a similar inhibitory behavior on neural responses. Inhibitory effect of re-enchantment L1 · pentanol-1 on oxidative damage to brain cells caused by isopropylbenzyl hydrogen peroxide This example was performed in an experimental procedure similar to that of Example 3. The CA1 spike group of the hippocampal slice decreases its amplitude with the influence of the concentration of cumene hydroperoxide. After adding 0.5 mM and LOmM of cumene hydroperoxide for 15 minutes, the amplitude of the CA1 spike group decreased to 70.5 ± 2.4% (η = 3) and 34 · 5 of the control amplitude series, respectively. ± 5.4% (η = 5). If these hippocampal slices were cultured with pentanol-1 for 5 minutes before adding cumene hydroperoxide, the peak group amplitude was 102.8 ± 1.9% (η = 4) of the amplitude of the prodrug control amplitude. After adding cumene hydroperoxide for 15 minutes, the amplitude dropped to 75.6 ± 31% (η = 4), and the intensity was about 2.11 times that without gefanol-1. Re-administration Example 5: The effect of phorbol-1 on the cell destruction caused by reperfusion surgery. The autogenous transplantation of dogs was used to evaluate the effect of phorbol-1 on free radical scavenging during reperfusion surgery. Mongrel dogs (n = 8_i 0 in each group) were anesthetized and cut from the peritoneal midline for bilateral nephrectomy. The excised kidneys were immersed in a 4 ° C perfusate after a period of blood loss. After 24 hours of cryopreservation, a subcutaneous cervical depression was implanted in the same dog. This paper size applies to China National Standard (CNS) A4 (210X297 mm) (Please read the precautions on the back before filling this page)

經濟部中央標準局員工消費合作社印製 516958 A7 ~^_— B7_ 五、發明説明¢4 ) ' -~~~-〜 於切除前的連續30分鐘及移植丨小時後連續的3〇分鐘 收集血液與尿液的樣品。實驗的變數包括如⑺/汕比灌 流液中芙醇-l(20mM)的存在與否,以及缺血持續的時間0 分鐘vs· 30分鐘)。腎功能的評定是根據切割前與移植後 的生化係數之比較,包括血尿素氮(BUN)、血清肌氨酸 酐、肌酸肝肅清力(CCr)、尿液流速、尿氮或鉀離子的分 次再吸收或排泄。並且在切割前、以及血管接合之前與 之後,以HPLC分析腎臟活組織的腺核苷酸濃度,同時 並對每個代表性的樣品作病理組織學的觀察。 在每一臂,移植後的數據顯示了腎功能的惡化狀 況。在切割如的每一組數據都大致相同,比較移植後3 分鐘絕血與30分鐘絕血的兩組數據(灌流液中含2〇μΜ 之芙醇-l).CCr 分別為 4·5±1·6 ml/min 與 2·8±0·5 ml/min ; 總鈉再吸收量分別為456±213 mmol/min與218±56 mmol/min,此數據比起不含芙醇_丨的控制組具有明顯的 進步· CCr 分別為 6·2±2·3 ml/min 與 5.1土1.5 ml/min ;總 納再吸收置分別為663±308 mmol/min與459土183 mmol/min ° 腎臟活體樣品的病理組織學部份,是以H&amp;e染劑 在光顯微鏡下進行觀察。在實驗中使用含芙醇_丨之灌流 液的腎臟組織,顯示出有較少的炎性細胞滲透、較少的 管膨脹與壞死、以及較少的出血斑。這些差異在絕血3〇 分鐘的這兩組表現地更明顯。 腎臟活組織的腺核苷酸濃度分析顯示出經過絕血的 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁)Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 516958 A7 ~ ^ _— B7_ V. Description of the invention ¢ 4) '-~~~-~ Blood was collected for 30 minutes before resection and 30 minutes after transplantation With urine sample. The experimental variables included the presence or absence of pentanol-1 (20 mM) in Rugao / Shanbi perfusion, and the duration of ischemia (0 min vs. 30 min). The evaluation of renal function is based on the comparison of biochemical coefficients before and after cutting, including blood urea nitrogen (BUN), serum creatinine, creatine liver clearing power (CCr), urine flow rate, urine nitrogen or potassium ions. Reabsorption or excretion. And before the cutting, and before and after the vascular junction, the adenosine concentration of the kidney biopsy was analyzed by HPLC, and the histopathological observation was performed on each representative sample. In each arm, post-transplantation data show deteriorating renal function. The data in each group were roughly the same at the time of cutting. The two groups of data were compared at 30 minutes and 30 minutes after transplantation (the perfusion solution contained 20 μM of pentanol-l). The CCr were 4.5 · ± 1 · 6 ml / min and 2 · 8 ± 0 · 5 ml / min; total sodium reabsorption amounts were 456 ± 213 mmol / min and 218 ± 56 mmol / min, respectively. The control group had significant progress.The CCr were 6.2 ± 2.3ml / min and 5.1 ± 1.5ml / min; the total sodium reabsorption was 663 ± 308mmol / min and 459 ± 183mmol / min. The histopathological part of the biological sample was observed under a light microscope with H &amp; e stain. Kidney tissue using perfusate in experiments showed less inflammatory cell penetration, less tube swelling and necrosis, and fewer bleeding spots. These differences were more pronounced in these two groups at 30 minutes of hemostasis. Analysis of the concentration of adenosine in kidney biopsy showed that the paper was sterilized. The paper size applies the Chinese National Standard (CNS) A4 (210X297 mm) (Please read the precautions on the back before filling this page)

516958 五、發明說明(/句 經濟部智慧財產局員工消費合作社印製 過氧化作用利用光學法偵測,♦ η 66 M ^ ^ ^ 、、田θ蛋白達到表大過氧化 的穩疋狀恶時,將之冷卻並加入edta (3祕)與則 使用01=) Γ反應終止。脂蛋白的氧化程度依使用或不 7冷'〖聚(丁基磺醯鈉)芙類(採用濃度介於1〇_5沢 以區分芙類效用,或依反應進行之前,或在 f應傳播期加人此芙類衍生物,觀察芙類衍生物加入時 期的效用差別效益。 τ 共軛二烯形成的動力學是以連續監視234nm的吸 光值來加以推斷。延遲時間的計算是吸光值曲線直線迅 速上升時的斜率加以外插法求得,其對應於傳播反應的 進行階段。脂質的氧化程度是用硫代巴比妥酸活性物 々(TBARS)來推疋,其以丙二醛(mal〇ndialdehyde)的 等饧物估异。反應的進行方式是以硫代巴比妥酸將脂蛋 白在95°C下作用1小時。將混合物冷卻至室溫後,所得 的衍生物以正丁醇加以萃取,再將萃取液用以螢光偵 測,使用激發光波長為515nm,而放射光波長為乃仏㈤。 將新鮮的人體脂蛋白置於PBS與AAPH中,或是置 於PBS與AMVN中,於37°C下反應24小時會使脂蛋白 發生氧化反應。在同時間加入丁基磺醯芙類定會抑制脂 蛋白氧化反應,抑制的效果依據其濃度而定。在所有的 例子中若是加入500mM的丁基磺醯芙類時,幾乎可以 完全抑制氧化反應(大部份都超過90%),而最小量的 TBARS產物。二價的Cu+2離子會使所有的脂蛋白產生 顯著的氧化反應,在Cu+2引起的HDL氧化反應中,加 (請先閱讀背面之注意事項再填寫本頁) 訂---------線! -ϋ n-- -n n I I n ϋ - 18 516958 A7 五、發明說明(/7) 一 入20mM的丁基磺醯芙類產生8〇%以上的抑制效果。根 據動力學的測量顯示,在Cu+2引起的共輕二稀形成反應 中17使加入^、里的丁基績醯芙類(1 〇mM )也會使傳播 反應的速率降低,而使延遲時間與尖峰時間顯著地延 長丁基〜芙類對脂蛋白氧化反應的高度抑制效果, 不僅是在反應的起始階段,同樣地在氧化反應的傳播階 段也是如此。 Λ方“列7 •芙醇與芙醇_2對人體Τ-淋巴血癌CEM細 胞的增生抑制效果 本實施例是以芙醇_1與芙醇_2測量它們對胎牛血清 引起的Τ-淋巴血癌CEM細胞增殖的抑制效果,藉由分 析增生細胞合成DNA時[Η3]胸腺核苷的結合,來評定芙 醇“與芙醇-2的抑制效果(Watabe,et al,j Natl以以以516958 V. Description of the invention (/ sentence Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs printed the peroxidation by optical method, ♦ η 66 M ^ ^ ^, when the field θ protein reached a stable state of severe peroxidation , Cool it and add edta (3 secret) and then use 01 =) Γ reaction stopped. The degree of oxidation of lipoproteins depends on whether or not it is cold. [Poly (butylsulfosulfonate) fusi (using a concentration between 10-5 沢 to distinguish fusi effects, or depending on the reaction before, or before f should spread Add this fusiform derivative and observe the difference in effectiveness of the fusiform derivative in the period of addition. Τ The kinetics of conjugated diene formation is inferred by continuously monitoring the absorbance at 234nm. The calculation of the delay time is the absorbance curve The slope when the straight line rises rapidly is obtained by extrapolation, which corresponds to the stage of the propagation reaction. The degree of oxidation of the lipid is deduced by the thiobarbituric acid active substance thorium (TBARS), which is based on malondialdehyde ( malondialdehyde) is estimated to be different. The reaction proceeds in the manner that lipoprotein is treated with thiobarbituric acid at 95 ° C for 1 hour. After the mixture is cooled to room temperature, the resulting derivative is n-butyl It is extracted with alcohol, and the extract is used for fluorescence detection. The wavelength of the excitation light is 515nm and the wavelength of the emitted light is Naaman. Put fresh human lipoprotein in PBS and AAPH, or in PBS and In AMVN, it will react for 24 hours at 37 ° C. Oxidation of lipoproteins. At the same time, the addition of butylsulfazone will inhibit the oxidation of lipoproteins, and the effect of inhibition depends on its concentration. In all cases, when 500mM butylsulfazone was added It can almost completely inhibit the oxidation reaction (most of them exceed 90%), and the minimum amount of TBARS products. The divalent Cu + 2 ions will cause all lipoproteins to have significant oxidation reactions, and HDL caused by Cu + 2 In the oxidation reaction, please add (please read the precautions on the back before filling this page). Order --------- line! -Ϋ n-- -nn II n ϋ-18 516958 A7 V. Description of the invention (/ 7) The addition of 20 mM sulfosulfuric acid produces an inhibition effect of more than 80%. According to kinetic measurements, 17% of the butyl disulfide was added to the co-light dilute formation reaction caused by Cu + 2. Fu (10 mM) will also reduce the rate of the propagation reaction, and make the delay time and spike time significantly prolong the high inhibitory effect of butyl ~ Fu on oxidation of lipoproteins, not only in the initial stage of the reaction, The same is true in the propagation stage of the oxidation reaction. "Column 7 • Inhibition of proliferation of human T-lymphocytic cancer CEM cells by pentanol and pentanol_2 This example measures cholesterol_1 and pentanol_2 on TEM of C-cells caused by fetal bovine serum The inhibitory effect of cell proliferation was analyzed by analyzing the binding of [Η3] thymidine during the synthesis of DNA by proliferating cells to evaluate the inhibitory effect of phoritol and pentol-2 (Watabe, et al, j Natl.

Inst· 1984, 72, 1365 )。將人體丁_淋巴血癌CEM細胞放 在含有10%胎牛血清的ΚΡΜΙ-164〇介質中進行培養,並 以椎藍染料隔離法偵測細胞的生命力。實驗進行的方式 是將芙醇-1或芙醇_2加入懸浮的腫瘤細胞中(5χ1〇3 cell/well ),而對照組的腫瘤細胞則不加入芙醇。每一組 實驗都先在C〇2培養器在37下培養〇·5小時,然後再加 入[H ]胸腺核昏(1 μ。),再經過4小時的培養後,將 細胞採集並計算[H3]胸腺核苷結合的數量。 因10%胎牛血清在人體T-淋巴血癌細胞所引起的結 合[H3]胸腺核苷的控制值為7〇31±322 cpm/well。當人體 T_淋巴也癌細胞暴露在芙醇下時(10-6至ι〇-4μ) ,[η3] 19 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ----- f靖先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 訂——.!-----線! 516958 A7 五、發明說明(Μ 經濟部智慧財產局員工消費合作社印製 胸腺核驻的結合度會大幅地減少,且隨著芙醇的劑量增 加則增殖反應也會急速減少。芙醇]的%。數值 為6·4±2·0μΜ。濃度〇 的芙醇 *田 ± &amp; Qn 〇 , . 〇0/ 夫転·1可邢來琅大的抑制 率f 9咖.9/。。經過實驗的比較後可發現若使用抗壞 =ί維他命C)要達到5G%的抑制率時所需要的劑量 為吴醇-1的1 0 〇倍〇 土言揭沾会士田上 樣的、、、σ果說明了水溶性芙醇可應 用在癌細胞,例如人體丁_、站Ρ 淋巴血癌細胞的增生抑制作用 上0 與訪_2對平滑肌細胞的增生 果 在油脂線與纖維斑中,作為具有連接組織與脂質之 糾結結構的平滑肌細胞的出現與生長,是判斷致粥瘤性 病變程度的關鍵因素(Ross,Nature,1993,362,8〇1)。 本a轭例疋以芙醇_ 1與芙醇_2測量它們對因1 〇之 牛血π引起的培養兔主動脈平滑肌細胞增殖的抑制效果 (Huang,et al· Eur· J. Pharmacol.,1992, 221, 381 )。從 兔的主動脈取下血管,除去内皮,具有2/3細胞的中層 切成為寬約1 mm的長條,再將這些長條切成正方塊並置 於一乾燥培養皿中。將培養皿注入含有丨〇%胎牛血清的 DMEM培養基。當細胞游離時將主動脈塊取出,使用位 於第3與第8代間的細胞,並以椎藍染料法偵測細胞的 生命力。 而主動脈平滑肌細胞的增殖作用是由DNA合成時 [H ]胸腺核替的攝入量偵測而得。在實驗之前,平滑肌細 胞(2.5xl〇4cell/well)在〇·5%胎牛血清中靜置培養48 (請先閱讀背面之注意事項再填寫本頁) 訂---------線! -·ϋ ϋ 20 本紙張尺度賴巾_ 準(CNS)A4規格(21〇 X 297公爱) II — n _ 516958 A7 發明說明(ί 1 ) 小時,再加入激發劑(5%的胎牛血清)與芙醇,此混合 液靜置24小時後再加入[H3]胸腺核苷(〇·2μ ci/weu)。 I過24小時的培養後將細胞採集,而結合的[h3]胸腺椋 苷可經由液態閃光計數器計算其放射量。每一項實驗都 以一組進行。芙醇-1及芙醇-2的抑制作用是以未經加入 芙醇日守激叙劑產生對照數值的百分比來表示。能引起Μ% 的最大抑制作用的濃度即為ICs〇。因5%胎牛血清在培養 兔主動脈平滑肌細胞所引起的[H3]胸腺核苷攝入量對照 值為7266±755 cpm/wel卜芙醇的加入(1〇-6至1〇_4M)能 大幅減少[H3]胸腺核苷的結合度,且隨著芙醇的劑量增 加,增生反應也會隨著減少。芙醇_丨的數值(n=7) 為〇·12±〇·3 mM 。濃度〇.lmM的芙醇]表現最大的抑 制作用為97.7土0.8%。經過實驗的比較後可發現若使用 抗壞血酸(維他命C)要達到5〇%的抑制作用時,所需 要的劑星類似。這樣的結果說明了水溶性芙醇對血管平 滑肌細胞的增生具有抑制效果,因此可以用來治療平滑 肌細胞的增生失調相關的病症,例如動脈粥狀硬化 (atherosclerosis)與血管成形術再阻塞(resten〇sis)。 雖然本發明已以一較佳實施例揭露如上,然其並非 用以限定本發明,任何熟習此技藝者,在不脫離本發明 之精神和範圍内,當可作各種之更動與潤飾,因此本發 明之保護範圍當視後附之申請專利範圍所界定者為準。 2 1 (請先閱讀背面之注意事項再填寫本頁) 11---------線! 經濟部智慧財產局員工消費合作社印製Inst. 1984, 72, 1365). Human D-lymphocytic cancer CEM cells were cultured in KPMI-164O medium containing 10% fetal bovine serum, and the vitality of the cells was detected by the cyanine dye isolation method. The experiment was performed by adding pentanol-1 or pentanol-2 to suspended tumor cells (5 x 10 cells / well), while tumor cells of the control group did not add pentanol. In each set of experiments, the cells were cultured in a CO 2 incubator at 37 ° C for 0.5 hours, and then [H] thymocyte faint (1 μ.) Was added. After 4 hours of incubation, cells were collected and calculated [ H3] Amount of thymidine binding. The control value of combined [H3] thymidine caused by 10% fetal bovine serum in human T-lymphocytes was 7031 ± 322 cpm / well. When human T_lymphocytes and cancer cells are also exposed to pentanol (10-6 to ι〇-4μ), [η3] 19 This paper size applies to China National Standard (CNS) A4 (210 X 297 mm)- --- f Jing first read the notes on the back before filling out this page) Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs --- !! ----- line! 516958 A7 V. Description of the invention (The binding degree of the printed thymic nucleus printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs will be greatly reduced, and the proliferative response will decrease rapidly as the dose of pentanol increases. Pentanol]% The value is 6.4 ± 2.0 μM. The concentration of phoritol * Tian ± &amp; Qn 〇,. 〇0 / Fu 転 1 can be Xinglailang large inhibition rate f 9 coffee. 9 / ... after the experiment After comparison, it can be found that if anti-corrosive = vitamin C) is required to reach a 5G% inhibition rate, the dosage required is 100 times that of wuol-1. The results show that water-soluble phoritol can be applied to the proliferation inhibition of cancer cells, such as human D- and P-lymphocytes. The proliferative effect of smooth muscle cells on fat lines and fibrous plaques, as a connection The appearance and growth of smooth muscle cells with a tangled structure of tissue and lipids is a key factor in determining the extent of atheromatous lesions (Ross, Nature, 1993, 362, 801). This a yoke example measures the inhibitory effect of bovine alcohol 1 and bovine alcohol 2 on the proliferation of cultured rabbit aortic smooth muscle cells caused by bovine blood π (Huang, et al · Eur · J. Pharmacol., 1992, 221, 381). The blood vessels were removed from the aorta of the rabbit, and the endothelium was removed. The middle layer with 2/3 cells was cut into strips with a width of about 1 mm. These strips were cut into squares and placed in a dry culture dish. The petri dish was filled with DMEM medium containing 10% fetal bovine serum. When the cells were free, the aortic block was removed, and the cells between the 3rd and 8th passages were used, and the vitality of the cells was detected by the cyanine dye method. The proliferation of aortic smooth muscle cells is detected by the intake of [H] thymic nucleus during DNA synthesis. Before the experiment, smooth muscle cells (2.5 × 104 cells / well) were allowed to stand for 48 hours in 0.5% fetal bovine serum (please read the precautions on the back before filling this page). Order --------- line! -· Ϋ ϋ 20 paper-size paper towels _ quasi (CNS) A4 size (21〇X 297 public love) II — n _ 516958 A7 Description of invention (ί 1) hours, then add stimulant (5% fetal bovine serum ) And phoritol, this mixture was left for 24 hours, and then [H3] thymidine (0.2 μ ci / weu) was added. After 24 hours of incubation, the cells were harvested, and the bound [h3] thymidine could be calculated by a liquid flash counter. Each experiment was performed in groups. The inhibitory effects of pentanol-1 and pentanol-2 are expressed as a percentage of the control value produced without the addition of pentanol daily stimulant. The concentration that can cause the maximum inhibition of M% is ICs. [H3] thymidine intake control value due to 5% fetal bovine serum cultured rabbit aortic smooth muscle cells. The addition of 7266 ± 755 cpm / wel bufanol (10-6 to 10-4M) It can greatly reduce the binding degree of [H3] thymidine, and the proliferative response will decrease as the dose of pentanol increases. The value (n = 7) of pentanol is 0.12 ± 0.3 mM. Phenol at a concentration of 0.1 lm] exhibited the largest inhibitory effect at 97.7 to 0.8%. After experimental comparison, it can be found that if ascorbic acid (vitamin C) is used to achieve 50% inhibition, the required dosage is similar. Such results indicate that water-soluble phoritol has an inhibitory effect on the proliferation of vascular smooth muscle cells, and therefore can be used to treat disorders related to dysplasia of smooth muscle cells, such as atherosclerosis and angioplasty restenosis. sis). Although the present invention has been disclosed as above with a preferred embodiment, it is not intended to limit the present invention. Any person skilled in the art can make various modifications and decorations without departing from the spirit and scope of the present invention. The scope of protection of the invention shall be determined by the scope of the attached patent application. 2 1 (Please read the notes on the back before filling this page) 11 --------- line! Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs

Claims (1)

516958 A8 第86116108號申請專,修正本修正日期 六、申請專利範圍 1 · 一種治療自由基所引 物,包括: |起之相關症狀的醫藥組成 一有效量的化合物: 其中F為-芙核;每個χ各自獨立地為⑽、 CH2)n-S03H、或(CH2)n-S03_的金屬鹽,其中每個n各自獨 立地為2-10之整數;以及m為 入山馬2-20之整數;以及 一藥學上可接受之載劑。 2. 如申請專利範圍第1項所述之醫藥組成物,其中X 為OH。 3. 如申請專利範圍第2項所述之醫藥組成物,其中m 為4-20之整數。 4·如申請專利範圍第3項所述之醫藥組成物,其中m 為10-20之整數。 5·如申請專利範圍第4項所述之醫藥組成物,其中該 夫核為C60芙核。 6.如申請專利範圍第丨項所述之醫藥組成物,其中χ 為(CH2)n_S〇3H、或(CH2)n-S〇/的金屬鹽。 7·如申請專利範圍第6項所述之醫藥組成物,其中m 為2-10之整數。 8·如申請專利範圍第7項所述之醫藥組成物,其中該 夫核為C60夫核。 22 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 a — — — — — — — — I — 1 — — — — — — — — — — — — — — — —516958 A8 Application No. 86116108, amended the date of this amendment Six, the scope of patent application 1 · A primer for the treatment of free radicals, including: | related symptoms from the medical composition of an effective amount of compounds: where F is-nucleus; each Each χ is independently a metal salt of ⑽, CH2) n-S03H, or (CH2) n-S03_, wherein each n is independently an integer of 2-10; and m is an integer of 2-20 ; And a pharmaceutically acceptable carrier. 2. The pharmaceutical composition according to item 1 of the scope of patent application, wherein X is OH. 3. The pharmaceutical composition according to item 2 of the scope of patent application, wherein m is an integer of 4-20. 4. The pharmaceutical composition according to item 3 of the scope of patent application, wherein m is an integer of 10-20. 5. The pharmaceutical composition as described in item 4 of the scope of patent application, wherein the husband's core is a C60 core. 6. The pharmaceutical composition as described in item 丨 of the patent application scope, wherein χ is a metal salt of (CH2) n_S03H, or (CH2) n-S0 /. 7. The pharmaceutical composition according to item 6 of the scope of patent application, wherein m is an integer from 2-10. 8. The pharmaceutical composition as described in item 7 of the scope of patent application, wherein the husband's core is a C60 husband's core. 22 This paper size applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm) (Please read the precautions on the back before filling out this page) Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs a — — — — — — — — I — 1 — — — — — — — — — — — — — — —
TW86116108A 1997-10-29 1997-10-29 Water-soluble fullerenol pharmaceutical composition TW516958B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW86116108A TW516958B (en) 1997-10-29 1997-10-29 Water-soluble fullerenol pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW86116108A TW516958B (en) 1997-10-29 1997-10-29 Water-soluble fullerenol pharmaceutical composition

Publications (1)

Publication Number Publication Date
TW516958B true TW516958B (en) 2003-01-11

Family

ID=27801038

Family Applications (1)

Application Number Title Priority Date Filing Date
TW86116108A TW516958B (en) 1997-10-29 1997-10-29 Water-soluble fullerenol pharmaceutical composition

Country Status (1)

Country Link
TW (1) TW516958B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1296054C (en) * 2004-05-14 2007-01-24 中国科学院上海应用物理研究所 Application of fuller alcohol as ramification of C60 in nourishing hair
WO2015101918A1 (en) * 2013-12-30 2015-07-09 Universidade Federal De Minas Gerais - Ufmg Antileishmanial compositions containing fullerol and use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1296054C (en) * 2004-05-14 2007-01-24 中国科学院上海应用物理研究所 Application of fuller alcohol as ramification of C60 in nourishing hair
WO2015101918A1 (en) * 2013-12-30 2015-07-09 Universidade Federal De Minas Gerais - Ufmg Antileishmanial compositions containing fullerol and use thereof

Similar Documents

Publication Publication Date Title
US5994410A (en) Therapeutic use of water-soluble fullerene derivatives
Yamamoto et al. Cycloprodigiosin hydrochloride, a new H+/Cl− symporter, induces apoptosis in human and rat hepatocellular cancer cell linesin vitroand inhibits the growth of hepatocellular carcinoma xenografts in nude mice
Narisawa et al. Inhibition of development of Methylinitrosourea-induced rat colon tumors by Indomethacin treatment
US11787804B2 (en) Compositions and methods for modulating hair growth
Zilversmit et al. Independence of arterial phospholipid synthesis from alterations in blood lipids
RU2161487C2 (en) Use of derivatives of 2-hydroxy-5-phenylazobenzoic acid as chemoprophylactic and chemotherapeutic agents incolon cancer
US5736576A (en) Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US6231894B1 (en) Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
CN101589026A (en) Method of treatment of glioma brain tumour
JP2005533812A (en) Pharmaceutical use of nitric oxide, heme oxygenase-1 and heme degradation products
JP2021152078A (en) Fucosidase inhibitors
TW200916101A (en) Telomerase activating compounds and methods of use thereof
EA023827B1 (en) Method of inducing apoptosis in a cell
CN101898978A (en) Eflornithine prodrug and conjugate and using method thereof
JP6676779B2 (en) Therapeutic agent for cancer and precancerous lesion, treatment method, and method for producing therapeutic agent
TW516958B (en) Water-soluble fullerenol pharmaceutical composition
CN114173773A (en) Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cells
Andervont Note on the transfer of the strain C3H milk influence through successive generations of strain C mice
US20140045796A1 (en) Transient hypoxia inducers and their use
WO2021023290A1 (en) Application of zinc pyrithione in treatment of lung cancer
JPH07508996A (en) Phenolized thioetheramines and their acyl derivatives for radioimaging and radiotherapy for use in the diagnosis and treatment of pigmentation diseases
CN113143924A (en) Application of thioimidazolidinone medicine in treating COVID-19 diseases
WO2020072279A2 (en) Deuterium depletion measurement
KR20080106897A (en) Compounds and methods for the treatment of cancer
WO2023016321A1 (en) Use of ensartinib or salt thereof in treatment of disease carrying met 14 exon skipping mutation

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees